Scott Van Wart
Overview
Explore the profile of Scott Van Wart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carrillo N, Malicdan M, Leoyklang P, Shrader J, Joe G, Slota C, et al.
Genet Med
. 2021 Jul;
23(11):2067-2075.
PMID: 34257421
Purpose: To evaluate the safety and efficacy of N-acetylmannosamine (ManNAc) in GNE myopathy, a genetic muscle disease caused by deficiency of the rate-limiting enzyme in N-acetylneuraminic acid (Neu5Ac) biosynthesis. Methods:...
2.
Van Wart S, Mager D, Bednasz C, Huizing M, Carrillo N
Drugs R D
. 2021 Apr;
21(2):189-202.
PMID: 33893973
Background: GNE myopathy is a rare genetic muscle disease resulting from deficiency in an enzyme critical for the biosynthesis of N-acetylneuraminic acid (Neu5Ac, sialic acid). The uncharged Neu5Ac precursor, N-acetylmannosamine...
3.
Lodise T, Van Wart S, Sund Z, Bressler A, Khan A, Makley A, et al.
Antimicrob Agents Chemother
. 2020 Nov;
65(3).
PMID: 33168615
Intravenous (i.v.) minocycline is increasingly used to treat infections caused by multidrug-resistant (MDR) Despite its being approved nearly 50 years ago, published information on its pharmacokinetic (PK) profile is limited....
4.
Gall J, Choi T, Riddle V, Van Wart S, Gibbons J, Seroogy J
Clin Pharmacol Drug Dev
. 2019 Jan;
8(8):1032-1041.
PMID: 30650259
Plazomicin is an aminoglycoside with in vitro activity against multidrug-resistant Enterobacteriaceae. A phase 1, randomized, double-blind, crossover study assessed the potential effects of plazomicin on cardiac repolarization (NCT01514929). Fifty-six healthy...
5.
Komirenko A, Riddle V, Gibbons J, Van Wart S, Seroogy J
Antimicrob Agents Chemother
. 2018 Oct;
62(12).
PMID: 30275092
Plazomicin is an FDA-approved aminoglycoside for the treatment of complicated urinary tract infections. In this open-label study, 24 adults with normal renal function or mild, moderate, or severe renal impairment...
6.
Rhodes N, Kuti J, Nicolau D, Van Wart S, Nicasio A, Liu J, et al.
Antimicrob Agents Chemother
. 2015 Dec;
60(3):1401-10.
PMID: 26666929
The percentage of time that free drug concentrations remain above the MIC (fT>MIC) that is necessary to prevent mortality among cefepime-treated patients with Gram-negative bloodstream infections (GNBSI) is poorly defined....
7.
Dunne M, Puttagunta S, Sprenger C, Rubino C, Van Wart S, Baldassarre J
Antimicrob Agents Chemother
. 2015 Jan;
59(4):1849-55.
PMID: 25561338
Dalbavancin is an intravenous lipoglycopeptide with activity against Gram-positive pathogens and an MIC90 for Staphylococcus aureus of 0.06 μg/ml. With a terminal half-life of >14 days, dosing regimens with infrequent...
8.
Marathe A, Van Wart S, Mager D
J Pharmacokinet Pharmacodyn
. 2010 Dec;
38(2):223-35.
PMID: 21165681
The purpose of this study was to examine the role of dose selection on population pharmacokinetic (PK) parameter estimation using a rapid binding approximation of a target-mediated drug disposition (TMDD)...
9.
Van Wart S, Phillips L, Ludwig E, Russo R, Gajjar D, Bello A, et al.
Antimicrob Agents Chemother
. 2004 Nov;
48(12):4766-77.
PMID: 15561855
Garenoxacin (T-3811ME, BMS-284756) is a novel, broad-spectrum des-F(6) quinolone currently under study for the treatment of community-acquired respiratory tract infections. This analysis assessed garenoxacin population pharmacokinetics and exposure-response relationships for...
10.
Ambrose P, Anon J, Owen J, Van Wart S, McPhee M, Bhavnani S, et al.
Clin Infect Dis
. 2004 May;
38(11):1513-20.
PMID: 15156435
The relationship between drug exposure and the time course of antimicrobial effect at the primary infection site for acute maxillary sinusitis has not previously been explored. This single-center, open-label study...